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Aims To examine the number and type of co-morbid long-term health conditions (LTCs) and their associations with all-
cause mortality in an atrial fibrillation (AF) population.
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Methods
and results
Community cohort participants (UK Biobank n= 502 637) aged 37–73 years were recruited between 2006 and
2010. Self-reported LTCs (n= 42) identified in people with AF at baseline. All-cause mortality was available for a
median follow-up of 7 years (interquartile range 76–93 months). Hazard ratios (HRs) examined associations
between number and type of co-morbid LTC and all-cause mortality, adjusting for age, sex, socio-economic status,
smoking, and anticoagulation status. Three thousand six hundred fifty-one participants (0.7% of the study popula-
tion) reported AF; mean age was 61.9 years. The all-cause mortality rate was 6.7% (248 participants) at 7 years.
Atrial fibrillation participants with >_4 co-morbidities had a six-fold higher risk of mortality compared to participants
without any LTC. Co-morbid heart failure was associated with higher risk of mortality [HR 2.96, 95% confidence
interval (CI) 1.83–4.80], whereas the presence of co-morbid stroke did not have a significant association. Among
non-cardiometabolic conditions, presence of chronic obstructive pulmonary disease (HR 3.31, 95% CI 2.14–5.11)
and osteoporosis (HR 3.13, 95% CI 1.63–6.01) was associated with a higher risk of mortality.
...................................................................................................................................................................................................
Conclusion Survival in middle-aged to older individuals with self-reported AF is strongly correlated with level of multimorbidity.
This group should be targeted for interventions to optimize their management, which in turn may potentially
reduce the impact of their co-morbidities on survival. Future AF clinical guidelines need to place greater emphasis
on the issue of co-morbidity.
                                                                                                                                                                                                                   
Keywords Atrial fibrillation • Co-morbidity • All-cause mortality • UK Biobank
Introduction
Atrial fibrillation (AF) is the commonest sustained arrhythmia with a
worldwide prevalence estimated to be more than 33 million people.1
The prevalence of AF is increasing globally, partly attributable to
improved surveillance and the increasing prevalence of lifestyle-
related cardiovascular disease risk factors. The presence of AF is
associated with a nearly two-fold increase in the risk of all-cause mor-
tality.2 Recently, death has been reported as the most frequent major
adverse clinical event among AF patients, with significantly higher
event rates than stroke or systemic embolism.3
Multimorbidity, defined as the presence of two or more long-term
conditions (LTC),4 or co-morbidity, defined as the presence of one
more LTC in addition to an index condition,5 is very common in
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people with AF.6–8 A few studies have investigated co-morbidity in
AF, with some variations in the sample size, LTCs considered, and
the observed findings. A large Swedish study of 272 186 patients with
incidental AF reported 69.5% prevalence of at least one other
co-morbid condition as compared to 29.2% in matched controls
(considered seven LTCs based on records from a national patient
register).6 Similarly, a study in Belgium reported significantly more
co-morbidities among 1830 AF patients when compared with the
controls (considered 14 LTCs based on general practice records).8
A study based in the USA using the Rochester Epidemiology Project
(REP) database found higher prevalence of most co-morbid condi-
tions in 1430 AF patients compared with their matched controls
(considered 19 LTCs based on hospital records).7
The association of co-morbidity with all-cause mortality in the
AF population has been studied to some extent previously.6,7,9–11
However, there are significant gaps in the existing knowledge on the
patterns of prevalence of co-morbidity in AF and any impact on mor-
tality. Most of the published studies have examined a limited number
of co-morbidities that included mostly cardiometabolic or chronic
obstructive pulmonary disease (COPD),6,9–11 with the exception of
the REP database study.7 Therefore, the effects, if any, of a range of
non-cardiometabolic co-morbid conditions on all-cause mortality
remain largely unknown. Furthermore, the relationship of multimor-
bidity with all-cause mortality in people with AF remains unclear.
The aims of this study were as follows:
(1) To compare the number and type of co-morbid LTCs and their
association with all-cause mortality in participants with and without
self-reported AF;
(2) To compare the effect of the presence of different co-morbid con-
ditions on the risk of all-cause mortality in participants with self-
reported AF.
Methods
Study design and data collection
UK Biobank is a large prospective cohort of 502 640 participants (age 37–
73 years) recruited between 2006 and 2010. The participants attended 1
of 22 assessment centres across England, Scotland, and Wales and
completed a touch screen and nurse-led questionnaire with information
on demographics, health-related behaviour, and self-reported LTCs at
the time of recruitment. The participants also gave consent for prospec-
tive data linkage to national mortality data. Participants provided full
informed consent to participate in UK Biobank, and this study was cov-
ered by the generic ethics approval for UK Biobank studies from the
NHS National Research Ethics Service (approval letter dated 17 June
2011, Ref 11/NW/0382).
Description of clinical variables and
outcomes
Age was categorized into >65 years and <65 years (based on CHA2DS2-
VASc cut-off), sex was used as a categorical variable, and socio-economic
status was classified into quintiles based on Townsend score (a measure
of deprivation in the UK); Category 1 was the least deprived, and
Category 5 was the most deprived category (https://census.ukdataser
vice.ac.uk/get-data/related/deprivation). Smoking status was classified into
two categories: non-smokers and previous/current smokers. The list of
42 self-reported LTCs was used based on the previously published litera-
ture on multimorbidity (Supplementary material online, Table S1).4,12
Chronic pain was defined as present if the participant reported pain that
had persisted for more than 3 months in at least one of the seven body
sites listed or ‘all over the body’; a group of 20 LTCs known to have pain
as one of the major symptoms were labelled as ‘painful conditions’ (see
Supplementary material online, Table S1).12 Presence of depressive
symptoms was defined based on the results of high Patient Health
Questionnaire (PHQ-2), a score of 2 or more was used as a cut-off.13
Multimorbidity was classified on the basis of count into three categories:
presence of no other LTCs, presence of 1–3 LTCs, and presence of 4 or
more LTCs. Multimorbidity was also categorized as cardiometabolic or
non-cardiometabolic, the latter including conditions used in the
CHA2DS2-VASc score. All-cause mortality was recorded by data linkage
with national UK mortality registers.
Statistical methods
The initial analysis involved using the data from the whole UK Biobank
cohort and was split into two stages via the following analysis plan. In the
first stage, we used data on individuals with and without self-reported AF,
and the aim was to quantify the risk of all-cause mortality between partici-
pants with and without self-reported AF. In this stage, demographic infor-
mation, smoking status, number, and type of co-morbid health conditions
were compared between participants with and without self-reported AF
using the v2 tests for categorical variables and the unpaired Student’s
t-tests for continuous variables. Cox’s proportional hazards multivariable
regression analysis was used to compare the all-cause mortality in differ-
ent participant categories based on presence of self-reported AF and the
number of other LTCs. Participants with no LTCs were used as the refer-
ence category, and five other categories were created for comparison
as described above. The models fitted were adjusted for age, sex,
Townsend quintile, and smoking status. Participants with missing values
were excluded from the regression modelling. In building the Cox mod-
els, all covariates were initially included in the model, and any non-
significant effects (at the 5% level) were removed one by one until only
significant variables remained. The results of this analysis were presented
as hazard ratios (HRs) and 95% confidence intervals (CI).
The second stage of the analysis was performed using data from partic-
ipants with self-reported AF only, and the aim was to compare the effect
of the presence of different co-morbid conditions on the risk of all-cause
mortality. In this analysis, a survival plot was used to compare cumulative
survival between self-reported AF participants with different numbers of
co-morbid LTCs (none, 1–3, 4 or more). A Cox’s proportional hazards
What’s new?
• Survival in middle-aged individuals with self-reported atrial
fibrillation was strongly correlated with the level of
multimorbidity.
• Presence of certain non-cardiometabolic conditions, such as
chronic obstructive pulmonary disease and osteoporosis, was
associated with a significantly higher risk of mortality, and the
strength of these associations was similar to those observed
with co-morbid cardiometabolic conditions such as heart
failure.
• Atrial fibrillation patients with co-morbidities should be tar-
geted for interventions to optimize their management, which
in turn may potentially reduce the impact of their co-morbid-
ities on survival.
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multivariable regression model was constructed using all-cause mortality
as outcome variable among participants with AF. Presence of any other
cardiometabolic LTC and presence of any other non-cardiometabolic
LTC were used as predictor variables in the same model. As before, the
models were adjusted for age, sex, Townsend quintile, and smoking sta-
tus. In addition, the regression models performed using participants with
AF were also adjusted for their anticoagulation status at baseline (on
warfarin—yes or no). As with the Stage 1 analysis, the model-building
process initially included all variables in the model, and any non-significant
effects (at the 5% level) were then removed one by one until only signifi-
cant variables remained. The results were presented with HRs and 95%
CI. The final part of this Stage 2 analysis was to construct individual Cox’s
proportional hazards multivariable regression models to study the
adjusted effect size for the presence of each individual LTC (excluding
those with a prevalence of < 1% among participants with AF) on all-cause
mortality. Finally, a forest plot was constructed demonstrating the
adjusted HRs for all-cause mortality for co-morbid individual LTCs
among participants with self-reported AF; for each cardiometabolic and
selected non-cardiometabolic condition (with a statistically significant
association). All missing values were excluded in all of the regression
models in Stage 2. The results are presented in detail in a table in the sup-
plementary section (Supplementary material online, Table S2).
In addition, the regression models described above were repeated
using age as a continuous variable for sensitivity analysis. These results are
also presented in the supplementary section (Supplementary material
online, Tables S3 and S4).
All statistical analyses were done using the R software (version 3.2.2).
Results
Participant characteristics
In total, 502 640 UK Biobank participants were included in the analy-
ses, whereas 3 participants were excluded due to unavailability of
information on all-cause mortality. At the time of recruitment, 3651
(0.7%) participants who enrolled in the UK Biobank reported having
AF. The mean age of participants was 61.9 years, and the range was
40–70 years. Table 1 compares the demographic characteristics,
smoking status, distribution of co-morbidity, and anticoagulation sta-
tus of participants with and without self-reported AF in the UK
Biobank at baseline. Participants with self-reported AF were signifi-
cantly older, more likely to be male, and more likely to be smokers
compared with participants without self-reported AF.
Distribution of co-morbidity in
participants with and without atrial
fibrillation
Approximately 80% of participants with self-reported AF had at least
one other co-morbid LTC compared to nearly 65% among partici-
pants without self-reported AF. The majority of participants with
self-reported AF (55.2%) had at least one other cardiometabolic con-
dition compared to 30.8% participants without self-reported AF.
Approximately 45% of AF participants were on anticoagulants com-
pared with 0.7% of participants without self-reported AF. Participants
with self-reported AF were more likely to have chronic pain
symptoms (47.6%) and co-morbid painful condition (23.7%) as com-
pared to participants without AF (43.6% and 16.7%, respectively).
Multimorbidity and survival in
participants with and without atrial
fibrillation
The median duration for follow-up was 7 years (interquartile range
76–93 months). Two hundred and forty-eight (6.7%) participants
with AF had died at the end of the follow-up period as compared to
14 171 (2.8%) participants without self-reported AF. Vascular deaths
were reported in 105 (2.5%) participants with self-reported AF com-
pared with 2895 (0.6%) participants without AF. Table 2 compares
the relationship between all-cause mortality and the number of LTCs
reported at baseline, among participants with and without self-
reported AF. The results were adjusted for age, sex, smoking, and
socio-economic status. Participants with self-reported AF had 107%
higher risk of mortality compared with participants in the reference
category with no LTCs. Participants with self-reported AF and four
or more other co-morbid conditions had nearly six-fold higher risk
of mortality as compared to the reference group.
Distribution of co-morbidity and survival
in participants with atrial fibrillation
Figure 1 compares the unadjusted survival among participants with AF
on the basis of number of associated co-morbid conditions. Nearly
one in five AF participants with four or more other co-morbid condi-
tions had died at the end of 7 years of follow-up, compared with
approximately 1 in 20 AF participants with no co-morbid conditions.
Table 3 shows the adjusted effect sizes for the presence of type of
co-morbid conditions (cardiometabolic and non-cardiometabolic) on
all-cause mortality in the AF population. The presence of a single car-
diometabolic condition (CHA2DS2-VASc conditions) was associated
with an 83% higher risk of mortality, whereas the presence of any sin-
gle non-cardiometabolic condition was associated with a 45% higher
risk of mortality.
Figure 2 compares the adjusted effect sizes for the presence of indi-
vidual cardiometabolic and non-cardiometabolic conditions on sur-
vival among AF participants. Notably, presence of co-morbid heart
failure was associated with the highest risk of mortality (HR 2.96, 95%
CI 1.83–4.80) among cardiometabolic conditions, whereas previous
history of stroke or transient ischaemic attack (TIA) co-morbid with
AF was not associated with higher risk of mortality (HR 0.85, 95% CI
0.52–1.39). Among non-cardiometabolic conditions, notably, pres-
ence of COPD (HR 3.31, 95% CI 2.14–5.11), osteoporosis (HR 3.13,
95% CI 1.63–6.01), and cancer (HR 2.13, 95% CI 1.53–2.98) co-mor-
bid with AF were associated with significantly higher risk of mortality
compared with AF participants without these conditions, respectively
(Figure 2). Among AF participants, the adjusted effect size for the
presence of co-morbid COPD and osteoporosis on mortality was
similar to the effect sizes observed for any cardiometabolic condition.
These results are presented in detail in Supplementary material
online, Table S2. The observed trend in results was unchanged in
the sensitivity analysis using age as a continuous variable (see
Supplementary material online, Table S3 and S4).
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Table 1 Participants with and without self-reported AF
Participants with
self-reported AF
(n5 3651)
Participants without
self-reported AF
(n5 498 986)
P-value
Demographics
Age (years), mean (SD) 61.9 (6) 56.4 (8) <0.001
Age 65–73 (years) 1201/3651 (32.9%) 72 687 (14.5%) <0.001
Female-sex 1159/3651 (31.7%) 272 306 (54.5%) <0.001
Townsend score
1 767/3648 (21%) 99 919/498 362 (20.1%) <0.001
2 783/3648 (21.4%) 99 335/498 362 (19.9%)
3 744/3648 (20.3%) 99 668/498 362 (20%)
4 733/3648 (20%) 99 662/498 362 (20%)
5 621/3648 (17.1%) 99 778/498 362 (20%)
Smoking—current/previous (vs. never smoked) 1833/3625 (50.5%) 224 252/496 060 (45.2%) <0.001
Distribution of multimorbidity
MM count—mean 1.74 1.19 <0.001
Number of co-morbid conditions
None 713/3641 (19.6%) 172 599/497 151 (34.7%) <0.001
1–3 2524/3641 (69.3%) 299 334/497 151 (60.2%)
>_4 404/3641 (11.1%) 25 218/497 151 (5.1%)
Presence of co-morbid cardiometabolic conditions (included in CHADS2VASC)
Presence of at least one cardiometabolic condition 2013/3641 (55.2%) 153 214/497 151 (30.8%) <0.001
Hypertension 1630/3641 (44.8%) 131 694/497 151 (26.5%) <0.001
Diabetes 331/3641 (9.1%) 25 172/497 151 (5%) <0.001
Coronary heart disease 430/3641 (11.8%) 22 301/497 151 (4.5%) <0.001
Stroke/TIA 258/3641 (7.1%) 8596/497 151 (1.7%) <0.001
Heart failure 97/3641 (2.7%) 706/497 151 (0.14%) <0.001
Peripheral vascular disease 13/3641 (0.4%) 1266/497 151 (0.25%) 0.22
Presence of co-morbid non-cardiometabolic conditions
Presence of at least one non-cardiometabolic condition 2173/3641 (59.7%) 260 418/497 151 (52.4%) <0.001
Chronic pain symptomsa 1732/3640 (47.6%) 216 988/496 804 (43.6%) <0.001
Painful conditiona 865/3641 (23.7%) 83 127/497 151 (16.7%) <0.001
Depressive symptoms (based on PHQ-2>1) 535/3426 (15.6%) 80 893/464 097 17.4%) 0.005
Asthma 426/3641 (11.7%) 57 867/497 151 (11.6%) 0.89
Dyspepsia 401/3641 (10.9%) 38 675/497 151 (7.7%) <0.001
Cancer 347/3641 (9.5%) 38 276/497 151 (7.7%) <0.001
Thyroid disorders 301/3641 (8.2%) 28 839/497 151 (5.7%) <0.001
Prostate disorders 153/3641 (4.2%) 8107/497 151 (1.7%) <0.001
Psoriasis/eczema 129/3641 (3.5%) 17 707/497 151 (3.5%) 0.96
Connective tissue disordersa 101/3641 (2.7%) 10 932/497 151 (2.1%) 0.018
COPD 99/3641 (2.7%) 8218/497 151 (1.6%) <0.001
Irritable bowel syndrome 77/3641 (2.1%) 11 417/497 151 (2.2%) 0.47
Osteoporosis 74/3641 (2.0%) 7968/497 151 (1.6%) 0.03
Diverticular disease 67/3641 (1.8%) 5338/497 151 (1.1%) 0.07
Migraine 66/3641 (1.8%) 14 324/497 151 (2.9%) <0.01
Glaucoma 64/3641 (1.7%) 5252/497 151 (1.1%) 0.03
Anxiety 60/3641 (1.6%) 8966/497 151 (1.8%) 0.48
Inflammatory bowel disease 31/3641 (0.8%) 4200/497 151 (0.8%) 0.96
Epilepsy 29/3641 (0.8%) 4027/497 151 (0.8%) 0.93
Treated constipation 5/3641 (0.1%) 398/497 151 (0.08%) 0.22
Chronic kidney disease 24/3641 (0.6%) 1287/497 151 (0.25%) <0.01
Chronic sinusitis 19/3641 (0.5%) 3084/497 151 (0.6%) 0.45
Bronchiectasis 18/3641 (0.5%) 1117/497 151 (0.2%) <0.01
Continued
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Table 1 Continued
Participants with
self-reported AF
(n5 3651)
Participants without
self-reported AF
(n5 498 986)
P-value
Meniere‘s disease 17/3641 (0.5%) 1359/497 151 (0.3%) 0.02
Endometriosis 17/3641 (0.5%) 4045/497 151 (0.8%) 0.02
Pernicious anaemia 16/3641 (0.4%) 1501/497 151 (0.3%) 0.13
Viral hepatitis 15/3641 (0.4%) 1322/497 151 (0.3%) 0.08
Chronic liver disease 11/3641 (0.3%) 9600/497 151 (1.9%) 0.13
Chronic fatigue syndrome 9/3641 (0.2%) 3642/497 151 (0.7%) 0.08
Alcohol problems 8/3641 (0.2%) 803/497 151 (0.2%) 0.38
Schizophrenia/bipolar disorder 8/3641 (0.2%) 1989/497 151 (0.4%) 0.08
Parkinson’s disease 7/3641 (0.2%) 851/497 151 (0.2%) 0.75
Multiple sclerosis 5/3641 (0.1%) 1772/497 151 (0.5%) 0.02
Other psychoactive substance abuse 1/3641 (0.03%) 97/497 151 (0.02%) 0.73
Dementia 1/3641 (0.03%) 123/497 151 (0.03%) 0.91
Polycystic ovary 1/3641 (0.03%) 622/497 151 (0.1%) 0.09
Anorexia or bulimia 0 370/497 151 (0.07%) 0.09
n= 502 637.
AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; MM, multimorbidity; PHQ-2, Patient Health Questionnaire; TIA, transient ischaemic attack.
aChronic pain symptoms: pain present for more than 3 months; painful conditions: back pain, joint pain, headaches (not migraine), sciatica, plantar fasciitis, carpal tunnel syn-
drome, fibromyalgia, arthritis, shingles, disc problem, prolapsed disc/slipped disc, spine arthritis/spondylitis, ankylosing spondylitis, back problem, osteoarthritis, gout, cervical
spondylosis, trigeminal neuralgia, disc degeneration, and trapped nerve/compressed nerve; connective tissue disorders: myositis/myopathy, systemic lupus erythematosus,
Sjogren’s syndrome/sicca syndrome, dermatopolymyositis, dermatomyositis, polymyositis, scleroderma, systemic sclerosis, rheumatoid arthritis, psoriatic arthropathy, polymyal-
gia rheumatica, and malabsorption syndrome/coeliac disease.
....................................................................................................................................................................................................................
Table 2 Relationship of multimorbidity with all-cause mortality in participants with and without self-reported AF
using multivariate Cox’s proportional hazards regression analysis
Predictor variables Hazard ratios (95% CI) P-value Regression coefficients
Age > 65 (against age < 65 as reference) 2.31 (2.23–2.40) <0.001 0.84
Sex—male (against female as reference) 1.72 (1.66–1.78) <0.001 0.54
Townsend score categories
Category 1: least deprived (reference) 1
Category 2 1.00 (0.94–1.05) 0.94 0.001
Category 3 1.08 (1.02–1.14) 0.001 0.081
Category 4 1.19 (1.13–1.26) <0.001 0.18
Category 5: most deprived 1.46 (1.39–1.54) <0.001 0.38
Smoking—current/previous (vs. never smoked as reference) 1.67 (1.61–1.73) <0.001 0.51
Participants classified into different groups based on presence of AF and the number of long-term conditions
Participants without any long-term conditions (LTCs) (reference) 1
AF present and no other LTCs 2.06 (1.40–3.04) <0.001 0.72
AF absent and 1–3 LTCs 2.07 (1.98–2.16) <0.001 0.73
AF present and 1–3 other LTCs 3.17 (2.70–3.73) <0.001 1.15
AF absent and 4 or more LTCs 4.25 (4.00–4.52) <0.001 1.44
AF present and 4 or more other LTCs 6.80 (5.23–8.83) <0.001 1.91
Concordance (measure of model performance) = 0.70
n= 502 637. UK Biobank participants (5261 excluded due to missing values); number of deaths = 14 206.
AF, atrial fibrillation; CI, confidence intervals; Outcome, all-cause mortality at 7 years.
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Discussion
Summary of findings
Multimorbidity was common among middle-aged and older partici-
pants, aged 40–70 years, recruited from a community setting with self-
reported AF. The majority of AF participants reported the presence of
at least one other co-morbid LTC with both cardiometabolic and non-
cardiometabolic co-morbidities prevalent in approximately 80% of the
participants. At the end of the 7 years of follow-up period, a dose–
response association was observed between level of multimorbidity
and all-cause mortality with an increase in the number of co-morbid
LTCs alongside self-reported AF being associated with lower chances
of survival. Presence of all individual cardiometabolic conditions was
associated with a significantly higher risk of mortality among AF partici-
pants, with the exception of stroke/TIA. Presence of certain non-
cardiometabolic conditions was also associated with a significantly
higher risk of mortality, notably the risk of mortality associated with
co-morbid COPD and osteoporosis was similar to the effect sizes
observed for any cardiometabolic condition. These results were
adjusted for age, sex, socio-economic status, smoking status, and anti-
coagulant status at baseline.
Figure 1 Cumulative survival plot showing probability of all-cause
mortality among self-reported AF participants with different levels
of multimorbidity. n= 3651; AF participants (107 excluded due to
missing values).
....................................................................................................................................................................................................................
Table 3 Relationship between presence of cardiometabolic and non-cardiometabolic co-morbidity and all-cause mor-
tality in AF participants using multivariate Cox’s proportional hazards model
Predictor variables Hazard ratios (95% CI) P-value Regression coefficients
Age > 65 (against age < 65 as reference) 1.47 (1.13–1.90) <0.001 0.38
Sex-male (against female as reference) 2.14 (1.54–2.98) <0.001 0.76
Townsend score categories
Category 1: least deprived
(reference)
1
Category 2 1.45 (0.92–2.28) 0.10 0.37
Category 3 1.89 (1.22–2.92) <0.001 0.63
Category 4 1.73 (1.11–2.69) 0.01 0.55
Category 5: most deprived 2.03 (1.30–3.16) <0.001 0.71
Smoking—current/previous (against
never smoked as reference)
1.28 (0.98–1.67) 0.065 0.24
Anticoagulation status—on warfarin
(against not on anti-coagulants as
reference)
1.34 (1.02–1.75) 0.031 0.29
Presence of at least one other cardio-
metabolic condition (against no co-
morbid cardiometabolic condition as
reference)
1.83 (1.36–2.45) <0.001 0.60
Presence of at least one other non-car-
diometabolic condition (against no
co-morbid non-cardiometabolic
condition)
1.45 (1.11–1.91) 0.006 0.37
Concordance (measure of model performance) = 0.68
n= 3651 participants with AF (107 excluded due to missing values); number of deaths = 241.
AF, atrial fibrillation; CI, confidence interval; Outcome, all-cause mortality at 7 years.
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Comparison of findings to other studies
and implications
The prevalence of co-morbidity observed in our study was similar to
those previously reported for people with AF. There are some key
similarities and differences between the findings of our study and
other studies examining the effects of co-morbidity on all-cause mor-
tality in AF population.6,7,9–11 All of the previous studies report a stat-
istically significant higher risk of mortality with co-morbid COPD
among AF participants; however, the effect sizes were smaller than
this study.6,9–11 In a much larger Swedish study, the effect sizes for
the presence of certain concomitant conditions on mortality were
evaluated in participants with AF in three different age groups.6
Among cardiometabolic conditions, co-morbid heart failure was
associated with the highest risk of mortality in AF participants
<65 years with a similar effect size as reported here.6 Similar to the
findings in our study, presence of cancer was also associated with a
high risk of mortality.6 The American study using the REP database
reported no statistically significant association for the presence of co-
morbid COPD, osteoporosis, and asthma with all-cause mortality
among participants with AF.7 However, these studies did not adjust
for smoking, socio-economic, and anticoagulation status at baseline
which are important potential confounding variables.6,7 In the
ROCKET AF trial, various cardiometabolic conditions (such as
stroke, diabetes, and heart failure) and COPD were found to have a
statistically significant association with all-cause mortality; however,
the list of conditions examined was not as comprehensive as our
study.14 The ORBIT-AF study reported higher all-cause mortality for
AF patients with co-morbid cancer but only studied the effect of can-
cer.15 Similarly, other studies have reported a significant association
of mainly cardiometabolic conditions co-morbid with AF, but
they have not examined the effects of non-cardiometabolic
conditions.16,17 In summary, the effects of non-cardiometabolic con-
ditions have not been studied comprehensively before, and most of
the previous studies have not adjusted for the effects of a wide range
of confounding factors in their models. Importantly, the distribution
of multimorbidity among AF patients and its relationship with mortal-
ity has not been studied before.
There are a number of implications of our findings. Co-morbidity
and multimorbidity should be taken into account in risk stratification
of patients with AF. The current guidelines for risk stratification in AF
patients is mainly based on determining the need for anticoagulation
for prevention of thromboembolism,18 which in turn is largely based
on using the CHADS2VASC score which only takes cardiometabolic
co-morbidity into account. The current guidelines for management
of AF do not consider the risk of mortality in risk stratification.
Recent evidence has shown that the risk of mortality is much higher
for patients with newly diagnosed AF as compared to the risk of
stroke3,19 and that patients are more likely to die of a cardiovascular
event, usually heart failure.20 Importantly, the degree of multimorbid-
ity as well as the co-morbidity of non-cardiometabolic conditions,
such as COPD and osteoporosis, may have to be considered when
calculating the risk of mortality in patients with AF. Further research
in this area needs to focus on different causes of mortality and other
clinical outcomes in the AF population, such as hospitalization, and
the role of co-morbid conditions in these relationships. Equally,
exploration of interventions that may help enhance patient capacity
to manage their chronic illnesses and multimorbidity are merited, as
there is emerging evidence that complex interventions focusing on
improving patient capacity for self-care may be effective in reducing
hospital admission in patients with multiple LTCs.21 Finally, both car-
diometabolic and non-cardiometabolic co-morbidities was very com-
mon among AF participants. This may have important implications
for polypharmacy and drug interactions. For example, nearly half of
the participants with AF in this sample reported having chronic pain
symptoms. This puts them at risk of potentially dangerous prescribing
such as the co-prescribing of non-steroidal anti-inflammatory agents
and anticoagulants.
Strengths
This study has certain key strengths such as a large sample size,
recruitment from different areas of the UK, good data completion
rates, and adjustment for multiple confounding factors.
Limitations
There are a few important limitations of our findings. First, all LTCs
including AF were self-reported and the diagnosis could not be veri-
fied from clinical notes. Secondly, participants with more LTCs are
likely to have more health care utilization, which in turn may poten-
tially increase the probability of detecting silent AF. In addition, infor-
mation on the duration and the type of AF (paroxysmal or persistent)
was not known, which may have influenced the risk of mortality. In
future, it may be possible to get information on Holter monitoring for
UK Biobank participants, which may help with better categorization
and validation of the self-reported AF cohort. The observed effect
sizes for LTCs had large CIs which could be attributed to the relatively
smaller sample size. It is possible that some participants in the cohort
may have other undiagnosed conditions that may potentially influence
the observed trends in the results.22 Finally, the UK Biobank
Figure 2 Forest plot of hazard ratio for the presence of different
cardiometabolic and non-cardiometabolic conditions and all-cause
mortality in participants with AF. n= 3651 (97 excluded due to
missing values). Depressive symptoms include PHQ-2 >_2 Results
adjusted for age, sex, socio-economic, smoking, and anticoagulation
status. CHD, coronary heart disease; PHQ, Patient Health
Questionnaire; PVD, peripheral vascular disease.
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population has a higher proportion of Caucasians and affluent people
participating compared with the UK general population.
Conclusions
Multimorbidity was highly prevalent in this middle-aged to older
cohort of patients with AF. Importantly, those with multimorbidity
are at increased risk of death over a follow-up period of 5–10 years.
These findings suggest that such patients should be prioritized for
interventions to optimize their management and in some cases to
adjust their lifestyle to reduce the impact of their co-morbidities on
survival. There may be a small number of multimorbid and frail
patients with AF, likely to have poor life expectancy, who should be
offered conservative and less invasive treatment options. However, it
is possible that, in the past, patients with multimorbidity may have
been denied effective treatments that might have improved their out-
come, and we would suggest that in most cases effective treatments
and interventions should not be withheld from these high-risk individ-
uals. The problem of co-morbidity and multimorbidity needs to be
given greater consideration in future AF guidelines.
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